Latest news with #ABVC
Associated Press
5 days ago
- Business
- Associated Press
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value
Silicon Valley, CA - ( NewMediaWire ) - June 03, 2025 - – ABVC BioPharma, Inc. (NASDAQ: ABVC) ('Company'), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that its Board of Directors approved a plan to distribute, one share of stock of AiBtl BioPharma Inc. ('AIBTL'), a corporation organized and existing and under the laws of the State of Delaware, as a dividend reward to its shareholders for each share of ABVC common stock owned by the shareholder (the 'AIBTL Shares'). Based on the Company's current holdings, the Company expects to distribute approximately 15M AIBTL Shares. The distrubtion shall take place after the AIBTL Shares are included in an effective registration statement under the Securities Act of 1933, of which there is no guarantee. AIBTL is one of the Company's subsidiaries and an entity with which ABVC holds certain licensing agreements, as disclosed in ABVC's public filings with the Securities and Exchange Commission. This distribution will mark the Company's first dividend payment. The Company believes that this dividend can boost shareholder confidence and trust in the Company's capabilities. 'I am proud of ABVC's journey and that it is in a position to reward its shareholders with a dividend distribution. This distribution shows our confidence in AiBtl's long-term potential and our commitment to providing value to ABVC shareholders.,' said Dr. Uttam Patil, ABVC Chief Executive Officer. AiBtl is working on developing the Company's Asian Healthcare business; ABVC is its major shareholder, holding 57.8%. The partnership with AIBTL is expected to enhance ABVC's strategic objectives in international business development for its CNS programs of the MDD and ADHD markets and establish partnerships with international pharmaceutical companies. About AiBtl BioPharma Inc. AiBtl BioPharma Inc. is a Delaware-based biopharmaceutical company focused on the development of botanical-based therapeutic candidates for central nervous system (CNS) disorders, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Leveraging a combination of traditional botanical knowledge and modern clinical research, AiBtl is advancing drug candidates derived from Polygala tenuifolia, a traditional medicinal herb. AiBtl operates with a strategic focus on Asia-Pacific markets and is exploring collaborative opportunities with global pharmaceutical partners to support late-stage development and commercialization. ABVC BioPharma currently holds a majority ownership stake in AiBtl. About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Uttam Patil Email: [email protected]
Associated Press
14-05-2025
- Business
- Associated Press
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance
SILICON VALLEY, CA - May 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received official notice from the Nasdaq Listing Qualifications Department confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. According to Nasdaq's notification dated May 13, 2025, ABVC's common stock successfully maintained a closing bid price at or above $1.00 for 10 consecutive trading days from April 29, 2025 to May 12, 2025, satisfying the exchange's compliance standard for the referenced rule. This development formally closes this deficiency matter. 'This is more than a compliance milestone - it is a clear validation of our turnaround strategy and unwavering commitment to shareholder value,' said Dr. Uttam Patil, ABVC Chief Executive Officer. Comparing fiscal year 2024 to 2023, ABVC has made significant strides: The reinstatement of Nasdaq compliance follows a period of focused restructuring, paving the way for future success. ABVC is currently in preliminary discussions with leading pharmaceutical and AI companies to co-develop its Phase III-ready candidates for Major Depressive Disorder (MDD) and ADHD, both multibillion-dollar global markets. 'We see this as a critical inflection point,' said Dr. Patil. 'ABVC is no longer just a clinical-stage biotech - we are building a platform for global commercialization, powered by science, supported by strategy, and our continued Nasdaq listing demonstrates our ability to meet high listing standards.' About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Dr. Uttam Patil Email: [email protected] View the original release on
Associated Press
01-05-2025
- Business
- Associated Press
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan
SILICON VALLEY, CA - May 1, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, oncology, and ophthalmology indications, today announced its financial results for the first quarter ended March 31, 2025, and shared updates on its strategic plan to explore the development of an AI-enabled agricultural facility in Taiwan. First Quarter 2025 Highlights In the first quarter of 2025, ABVC recognized a parcel of land in central Taiwan valued at $7,670,000 as a strategic asset. The Company is currently assessing the feasibility of developing this site into a state-of-the-art, AI-integrated agricultural facility designed to meet Good Agricultural Practices (GAP) standards. There can be no assurance that the project will be implemented as currently envisioned, or that any future development on the site will be successfully completed. If implemented, the project could leverage local AI capabilities to enable precision-controlled agriculture and contribute to a more sustainable and traceable botanical supply chain. This strategic initiative aligns with ABVC's long-term vision to enhance vertical integration, improve material consistency, and support its future botanical drug pipeline. 'We believe this potential AI-driven agricultural project reflects our forward-looking approach to sustainable pharmaceutical innovation,' said Dr. Uttam Patil, CEO of ABVC BioPharma. 'As we continue to advance our clinical pipeline, we are also taking steps to evaluate infrastructure that could support long-term scalability.' The Company emphasized that the land recognition follows applicable accounting standards and responds to prior disclosures related to asset valuation methodology in the 2024 Form 10-K. Selected Financial Data for Q1 2025 (unaudited): ABVC remains committed to executing its clinical development programs and evaluating strategic infrastructure opportunities to support long-term commercialization and partnership growth. About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct global clinical trials through Phase III. For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit Visit for more information on BioLite Japan. ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit Forward-Looking Statements This press release contains 'forward-looking statements,' including statements regarding the Company's plans to develop an agricultural facility in Taiwan Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Dr. Uttam Patil Email: [email protected]
Associated Press
16-04-2025
- Business
- Associated Press
UPDATE: ABVC BioPharma Announces 2024 Financial Results
Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 16, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leveraging its asset-light, partnership-driven model, today announced its financial results for the fiscal year ended December 31, 2024, marking a pivotal year of operational transformation and financial improvement. Revenue Growth of 234% Fueled by Global Licensing Milestones ABVC reported total revenues of $509,589 in 2024, representing a 234% increase compared to $152,430 in 2023. This significant growth was primarily driven by milestone payments collected from the Company's global licensing partners in CNS, oncology, and ophthalmology therapeutic areas. Importantly, ABVC remains eligible to receive up to an additional $18.3 million in milestone payments under existing licensing agreements, which, if received, will provide strong non-dilutive funding visibility to support future growth. Operating Expenses Reduced by 21% Reflecting Cost Discipline Total operating expenses were reduced to $5.21 million in 2024, down 21% from $6.62 million in 2023. The decline was primarily driven by: This demonstrates ABVC's successful shift to a capital-efficient, partnership-focused operating model. Stock-Based Compensation Aligns Talent Retention with Long-Term Growth ABVC significantly increased the use of stock-based compensation in 2024 to $2.77 million, compared to $0.19 million in 2023, preserving cash while aligning employees and consultants with long-term shareholder value creation. EPS Improves by 77% Driven by Strong Execution Net loss attributable to ABVC narrowed from $7.79 million in 2023 to $4.90 million in 2024. Basic and diluted loss per share improved significantly from $(1.80) to $(0.42), reflecting a 77% year-over-year improvement. Remaining Licensing Milestone Income Provides Strong Revenue Visibility Future milestone payments remain subject to the achievement of specified development and regulatory events outlined in each licensing agreement and therefore such payments are not guaranteed. Management Commentary '2024 was a breakthrough year for ABVC. We delivered strong revenue growth, executed disciplined cost management, and validated our partnership-driven business model. With over $18 million of contracted milestone payments remaining available under licensing agreements, we believe ABVC is uniquely positioned to drive long-term shareholder value without relying on dilutive financings.' - Uttam Patil, Ph.D., Chief Executive Officer of ABVC About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Dr. Uttam Patil Email: [email protected]
Associated Press
15-04-2025
- Business
- Associated Press
ABVC BioPharma Announces 2024 Financial Results
Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 15, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leveraging its asset-light, partnership-driven model, today announced its financial results for the fiscal year ended December 31, 2024, marking a pivotal year of operational transformation and financial improvement. Revenue Growth of 234% Fueled by Global Licensing Milestones ABVC reported total revenues of $509,589 in 2024, representing a 234% increase compared to $152,430 in 2023. This significant growth was primarily driven by milestone payments collected from the Company's global licensing partners in CNS, oncology, and ophthalmology therapeutic areas. Importantly, ABVC remains eligible to receive up to an additional $18.3 million in milestone payments under existing licensing agreements, which, if received, will provide strong non-dilutive funding visibility to support future growth. Operating Expenses Reduced by 21% Reflecting Cost Discipline Total operating expenses were reduced to $5.21 million in 2024, down 21% from $6.62 million in 2023. The decline was primarily driven by: This demonstrates ABVC's successful shift to a capital-efficient, partnership-focused operating model. Stock-Based Compensation Aligns Talent Retention with Long-Term Growth ABVC significantly increased the use of stock-based compensation in 2024 to $2.77 million, compared to $0.19 million in 2023, preserving cash while aligning employees and consultants with long-term shareholder value creation. EPS Improves by 77% Driven by Strong Execution Net loss attributable to ABVC narrowed from $7.79 million in 2023 to $4.90 million in 2024. Basic and diluted loss per share improved significantly from $(1.80) to $(0.42), reflecting a 77% year-over-year improvement. Remaining Licensing Milestone Income Provides Strong Revenue Visibility Future milestone payments remain subject to the achievement of specified development and regulatory events outlined in each licensing agreement and therefore such payments are not guaranteed. Management Commentary '2024 was a breakthrough year for ABVC. We delivered strong revenue growth, executed disciplined cost management, and validated our partnership-driven business model. With over $18 million of contracted milestone payments remaining available under licensing agreements, we believe ABVC is uniquely positioned to drive long-term shareholder value without relying on dilutive financings.' - Uttam Patil, Ph.D., Chief Executive Officer of ABVC About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Dr. Uttam Patil Email: [email protected]
